A Prospective, Open-label, Single Center Abatacept in IgG4-Related Disease 10-patient Proof-of-concept Study
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2018
Price : $35 *
At a glance
- Drugs Abatacept (Primary)
- Indications Immunodeficiency disorders
- Focus Proof of concept; Therapeutic Use
- 14 Nov 2018 Planned End Date changed from 1 Mar 2020 to 20 Jun 2020.
- 14 Nov 2018 Planned primary completion date changed from 1 Oct 2019 to 21 Dec 2019.
- 14 Nov 2018 Status changed from not yet recruiting to recruiting.